An open label, multi-centre, phase III, subject initiated safety study of ME-609 [aciclovir/hydrocortisone; Lipsovir; Medivir AB] in treatment of recurrent herpes simplex labialis in adolescents,

Trial Profile

An open label, multi-centre, phase III, subject initiated safety study of ME-609 [aciclovir/hydrocortisone; Lipsovir; Medivir AB] in treatment of recurrent herpes simplex labialis in adolescents,

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2011

At a glance

  • Drugs Aciclovir/hydrocortisone (Primary)
  • Indications Herpes labialis
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Oct 2010 Results presented as a poster at the American Osteopathic Association's (AOA) 115th Osteopathic Medical Conference and Exposition.
    • 19 Mar 2008 Results from the phase III program reported in a Medivir media release.
    • 13 Feb 2008 Results from the Lipsovir phase III program are expected in late March or early April 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top